Hypothesis:Anti-[18F]FACBC PET-CT will adequately detect local and extraprostatic recurrence,
and lead to better characterization of disease status in restaging patients.
This is a study that will test a compound (chemical substance) that has a small amount of
radioactivity attached to it. This substance has a natural tendency to go to prostate tissue.
The substance is called [18]FACBC and it is given in the form of an injection into a vein.
After the substance reaches the prostate, scans called PET or Positron Emission Tomography,
are done. This is similar to having CAT scans or x-rays. Usually a compound called [18]FDG is
used for PET scans but this substance is eliminated by the kidneys and cannot reach the
prostate. This substance called [18]FACBC is not eliminated by the kidneys and may allow
tumors in the prostate to be seen better. It is sometimes difficult to tell if a growth on
the prostate is cancer with scans or x-rays that are usually done.
Anti-[18F]FACBC PET-CT will be compared to ProstaScint (In-capromab pendetide) which is the
conventional imaging for prostate cancer. Investigators will be blinded of the intervention.
This study will look at how the [18]FACBC goes into the prostate tissue and determine its
ability to detect recurrent prostate cancer.